Dr. Leighl on Maintenance Therapy as Last Highlight of Lung Cancer from 2012


PARAMOUNT SchemaThe last portion of Dr. Leighl's program on "Highlights of Lung Cancer from 2012" covered maintenance therapy, specifically focusing on the latest report of results from the PARAMOUNT trial, which demonstrated a significant survival benefit for maintenance Alimta (pemetrexed) continued after four cycles of the first line combination of cisplatin and Alimta.

Dr. Leighl's Highlights in Lung Cancer from 2012: MEK Inhibitor Therapy for KRAS Mutation-Positive NSCLC


Pre and post MEKiThe next portion of Dr. Leighl's "Highlights of Lung Cancer from 2012" webinar focused on exciting research presented at ASCO 2012 and very recently published on the potential efficacy of a new class of targeted therapy, called MEK inhibitors, for the large subset of patients who have a KRAS mutation.

Subscribe to Natasha Leighl